Magnesium and blood pressure: small drops, mostly in people with high blood pressure or low magnesium
Bottom line: Magnesium has Grade C evidence for small blood-pressure reductions in pooled trials, mainly in participants with low magnesium or with high blood pressure already on medication; results varied, and changes were not significant with normal blood pressure.
Small effect, mixed certainty. The newest meta-analysis (Argeros 2025, 38 trials, 2,709 adults) found systolic pressure about 2.8 mmHg and diastolic about 2.1 mmHg lower than placebo, close to the earlier Zhang 2016 result (2.0 and 1.8 mmHg at a median 368 mg a day for 3 months). The drop was concentrated in people with high blood pressure who already took blood pressure medicine and in people with low blood magnesium; in people with normal blood pressure it was not statistically significant. Results varied a lot between trials (I² 78 to 88%). In 2022 FDA said it would not object to a qualified claim that diets with adequate magnesium may reduce the risk of high blood pressure, worded to say the evidence is inconsistent and inconclusive. Grade C.
Reviewed . We sell some of what we grade.

Editorial section. Research summaries are not product claims and contain no product links or offers. A summary is never proof that any product works.
- The question
- Do magnesium supplements lower blood pressure, by how much and in whom, and where does the often-quoted 2 mmHg figure come from?
- Study design
- Meta-analyses of randomized placebo-controlled trials. Argeros 2025 (Hypertension): 38 trials lasting at least 4 weeks, 2,709 adults, 82 to 637 mg of elemental magnesium a day (median 365 mg) for a median 12 weeks, in ten forms led by oxide, aspartate and chloride; only one trial used a glycine form. Subgroups: 17 trials in people with high blood pressure (6 on blood pressure medicine, 9 untreated), 8 in people with normal blood pressure and 8 in people with low blood magnesium (0.74 mmol/L or below). Zhang 2016 (Hypertension): 34 double-blind trials, 2,028 adults, median 368 mg a day for a median 3 months. Kass 2012 (Eur J Clin Nutr): 22 trials, 1,173 people, 120 to 973 mg a day (mean 410 mg) for 3 to 24 weeks. Dibaba 2017 (Am J Clin Nutr): 11 trials, 543 people with insulin resistance, prediabetes or another chronic disease, 365 to 450 mg a day for 1 to 6 months. Rosanoff 2021 (Nutrients): 49 trials sorted by blood pressure and treatment status and tallied, without pooling. [1][2][3][4][5][6][7]
- What they found
- Argeros 2025: overall, systolic pressure fell 2.81 mmHg (95% CI 1.29 to 4.32) and diastolic 2.05 mmHg (0.88 to 3.23) more than on placebo. In people with high blood pressure, 2.96 systolic and 2.10 diastolic. In those already on blood pressure medicine, 7.68 systolic (2.69 to 12.67); in untreated high blood pressure, systolic 0.90, not significant (CI from a 3.94 drop to a 2.14 rise), and diastolic 1.88. In people with low blood magnesium, 5.97 systolic (3.41 to 8.52) and 4.75 diastolic, with no significant systolic change in people whose magnesium was normal. In people with normal blood pressure, no significant change. There was no dose-response relationship (all P 0.20 or higher), so higher doses did not clearly work better. Zhang 2016: systolic 2.00 mmHg lower (0.43 to 3.58) and diastolic 1.78 lower (0.73 to 2.82), with blood magnesium up 0.05 mmol/L; about 300 mg a day, or one month, looked enough to see a change. Kass 2012: about 3 to 4 mmHg systolic and 2 to 3 diastolic, larger above 370 mg a day and in crossover trials. Dibaba 2017: 4.18 systolic and 2.27 diastolic in people with insulin resistance, prediabetes or chronic disease. Rosanoff 2021: trials in people with controlled high blood pressure or normal pressure showed no change even above 600 mg a day, while all 10 trials in people with uncontrolled high blood pressure despite medication showed drops at 240 to 607 mg a day. [1][2][3][4][5][6][7]
- Limitations
- Most trials were small and short (median 12 weeks). In Argeros 2025, 25 of the 38 trials had some risk-of-bias concerns and 4 were high risk, mostly because randomization was poorly reported; results varied widely and the authors could not explain why. Forms, doses, how pressure was measured (seated, standing or over 24 hours) and diets differed, and most trials did not record how much magnesium people ate. The large drop in people on medicine rests on 6 trials and the low-magnesium result on 8, so both are leads rather than settled numbers. No trial measured heart attacks, strokes or deaths. Only one trial used a glycine form, so these results do not speak directly to the glycinate we sell. Rosanoff 2021 counted trials as positive or negative rather than pooling effect sizes. Funding and interests: Argeros 2025's senior author holds an Australian NHMRC grant and reports speaker fees and advisory roles with drug and device companies; the other authors report none. The FDA review answered a petition filed on behalf of The Center for Magnesium Education and Research.
- What this does not mean
- These trials do not show that magnesium treats or prevents high blood pressure or any disease, and magnesium is not a substitute for blood pressure medicine. Our claim for the magnesium glycinate we sell is structure/function only: supports muscle relaxation and a calm wind-down. We make no blood pressure claim for it. If your blood pressure is high or you take blood pressure medicine, talk with a clinician before adding magnesium; the larger drops were seen in people already on medicine, which is a reason to involve your prescriber, not to change anything on your own. Nuts, seeds, beans, leafy greens and whole grains supply magnesium too. NIH sets the adult upper limit for supplemental magnesium at 350 mg elemental a day; many of these trials gave more, and higher doses often cause diarrhea. People with kidney disease, or who take antibiotics, bisphosphonates or other drugs that interact with magnesium, should ask a clinician first. Knowing your numbers matters more than any supplement, so a regular blood pressure check is the place to start.
- Sources
- Argeros Z et al. Hypertension. 2025;82(11):1844-1856. Meta-analysis, 38 trials, 2,709 adults. doi.org/10.1161/HYPERTENSIONAHA.125.25129
- Zhang X et al. Hypertension. 2016;68(2):324-333. Meta-analysis, 34 double-blind trials, 2,028 adults. doi.org/10.1161/HYPERTENSIONAHA.116.07664 Our summary: Effects of Magnesium Supplementation on Blood Pressure
- Kass L, Weekes J, Carpenter L. Eur J Clin Nutr. 2012;66(4):411-418. Meta-analysis, 22 trials, 1,173 people. doi.org/10.1038/ejcn.2012.4
- Dibaba DT et al. Am J Clin Nutr. 2017;106(3):921-929. Meta-analysis, 11 trials in insulin resistance, prediabetes or chronic disease. doi.org/10.3945/ajcn.117.155291
- Rosanoff A, Costello RB, Johnson GH. Nutrients. 2021;13(1):195. Categorized review of 49 trials. doi.org/10.3390/nu13010195
- US FDA. Qualified health claim for magnesium and reduced risk of high blood pressure, January 10, 2022. www.fda.gov/food/hfp-constituent-updates/fda-announces-qualified-health-claim-magnesium-and-reduced-risk-high-blood-pressure
- NIH Office of Dietary Supplements: Magnesium fact sheet for health professionals (upper limit, food sources, interactions). ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/
Related summaries
Spot an error? Email hello@everstackhealth.com and we will correct it within 48 hours.